Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases Read more
FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients Read more
Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy Read more
Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole Read more
Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre Read more